David Dodd
Mentioned in 3 analyzed podcast episodes across 3 shows
CEO of Geovax, a biotech company, who has shifted the company's vaccine development priorities in response to regulatory environment changes, moving focus from COVID and MPOX vaccines to lower-risk MPOX vaccine development. Also noted as co-author of 'Security Analysis,' a work that has influenced value investing approaches among investors like Wil VanLoh.
Episode Appearances
Marketplace All-in-One · Feb 17, 2026
Why would the Fed loosen mortgage regulations?
“CEO of Geovax biotech company; shifting vaccine priorities due to regulatory environment uncertainty”
Marketplace · Feb 17, 2026
Why would the Fed loosen mortgage regulations?
“CEO of Geovax biotech company shifting priorities from COVID and MPOX vaccines to focus on lower-risk MPOX vaccine”
The Tony Robbins Podcast · Feb 7, 2026
Why Energy May Be the Best Investment of the Next Decade with Wil VanLoh
“Co-author of 'Security Analysis'; influenced Wil VanLoh's value investing approach at TCU”